Friday, 06 Dec 2019


Date Typesort ascending Title Save
29 Jun 2018 Social European Commission has approved XELJANZ® (tofacitinib citrate) 5 mg twice daily (BID) in combination with methotrexate (MTX) for the treatment of adults with active psoriatic arthritis (PsA) with an inadequate response to DMARDs
24 Feb 2017 Social Study of >43K Pso, PsA, AS pts shows 14-34% increase risk for depression; but not for suicide or suicidal ideation.
18 Jun 2015 Social Arthritis mutilans review & defined:digital telescoping/shortening, flail jts, xray resorption, pencil-in-cup change
17 Dec 2017 Social FDA approves Xeljanz (tofacitinib) for use in adults with psoriatic arthritis, alone or in combo w/ MTX/DMARDs. But warns agains combining with biologics, cyclosporine or azathioprine as these have not been studied.
17 Feb 2017 Social RT @DrRachelTate: RAPID3 as a potential useful tool for PsA. Arthur Kavanaugh, MD and Eric Ruderman, MD #rwcs2017 @RWCSmtg @RheumNow https:…
22 Oct 2018 Social RT @japaoli19: Abstract 1631 20% incidence of uveitis in SpA with IBD phenotype having the highest incidence #ACR18 @rheumnow…
29 Aug 2019 Social Amgen Inc will buy Celgene Corp’s psoriasis drug Otezla for $13.4 billion in cash, clearing the way for Bristol-Myers Squibb to go ahead with its $74 billion deal for Celgene by the end of the year.
12 Nov 2019 Social RT @DrPetryna: @RheumNow #ACR19 #acrbest abs2470 ⬆️serum calprotectin in PsA pts associated w/presence of carotid plaque, ⬆️intima-media th…
05 Nov 2017 Social RT @japaoli19: Low dose CT detects more spinal progression vs xray in AS measured by ct syndesmophyte sc #582 #ACR17 @rheumnow https://t.…
27 Jun 2016 Social RAPID3 gives similar outcome info to BASDAI and ASDAS in a cross sectional study of 85 AS patients
09 Sep 2018 Social Excellent open review of obesity's influence on disease onset (RA, PsA), pathogenesis, disease progression, functional consequences and treatment interference.
18 Apr 2017 Social Corrona study 1,567 PsA shows patients w/ dactylitis or enthesitis had more Dz activity, Pain, Fatigue, low work,HAQ
02 Oct 2015 Social Looking at 2 different datasets, having PsA confers a 30+% risk of Cardiovascular dz
15 Oct 2019 Social Followup of 783 tofacitinib‐treated psoriatic arthritis patients finds increases in LDL and HDL 9% to 14% after 3 and 6 months of therapy with a low risk of HTN or MACE events
13 Nov 2019 Social RT @DrKanikaMonga: Abstract #0626 Are there really differences between non-radiographic and radiographic axial spondyloarthritis? Data from…
06 Nov 2017 Social Plenary abst#1787 Landawe presents Atlas 5 study, continuation of ADA is assoc w/ signif less flares in nr-AxSpApts…
07 Oct 2016 Social Am I wrong?Otezla warnings overstate risk of depression % wt loss; yet understate diarrhea 9% & D/C for diarrhea <2%
25 May 2017 Social Tight control (TC) trial in PsA (TiCOPA) shows that TC is twice costly & QALYs- not cost-effective in most analyses
30 Jul 2015 Social PSOLAR registry Infection risk w/ age, DM, smoking, prior Infx, INFLX, ADA. Low rate w/ Stelara 0.83 & ETN 1.47/100PY
22 Mar 2018 Social FDA Approves Ilumya (tildrakizumab for Moderate-to-Severe Plaque Psoriasis. It binds p19 subunit of IL-23, inhibiting binding to IL-23 receptor. Given as 100 mg sc at Wk 0, 4 & q 12wks; 2nd IL-23 inhib approved for Pso.